Navigation Links
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform using protein misfolding, identified as a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com

Contact

For Reata Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reata Synthetic Triterpenoids Profiled Nature Reviews Cancer
(Date:8/25/2008)...vention and Treatment Strategies--, PHILADELPHIA,...e,discovered gene mutations that are the main caus... neuroblastoma. In addition, the researchers found...n high-risk forms of,non-inherited neuroblastoma, ...very enables us to offer the first genetic tests t...
(Date:8/25/2008)...atient calls it a ,miracle, LATHAM, N.Y., Aug. 2...age Guided Radiation Therapy program at Community ...cancer patients using RapidArc(TM),radiotherapy te..., an,advancement that delivers a highly-precise im...) treatment in two minutes or less., RapidArc tre...
(Date:8/25/2008)... CLL Retreatment and Japanese Development Studies ...N, Denmark, August 25 /- Ge...ofatumumab in chronic lymphocytic,leukemia and non...nced today plans to begin four studies of,ofatumum...cular,non-Hodgkin,s lymphoma (NHL) this year., "G...
(Date:8/22/2008)...ust 22 /-, - Dangerous Bacteria Infe...etimes something well-tried can also be innovative... to be very antimicrobial. This,ability is now pla...gerous,hospital germs. In a worldwide noted field ...c in Wandsbek in Hamburg, Germany, was equipped wi...
Breaking Medicine Technology:Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 3Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 714 1Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 714 2Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference 712 1Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference 712 2Beaumont Patients 1st to get Next Generation of Radiation Treatment 337 1Beaumont Patients 1st to get Next Generation of Radiation Treatment 337 2Repeat steroids to premature infants linked to cerebral palsy 1654 1Repeat steroids to premature infants linked to cerebral palsy 1654 2
...Selective Anti-VEGF Antibodies Inhibited Tumor Gro...Cancer Model -, , - Peregrine,s Antibodies that Se...lly Have Advantages over Non-Selective Approaches ... Fully Human,Antibody Support , Advancing Peregrin...LOS ANGELES and TUSTIN, Calif., April 16, 2007,/PR...
...pril 16, 2007 /PRNewswire/ -- Expression,Genetics,...,clinical study evaluating the Company,s lead drug...University of Alabama at,Birmingham and , evaluate... biological activity of the EGEN-001 in 13 patient...r. The product,utilizing the Company,s proprietar...
Other Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 2Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 3Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 4
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...A new dryer that is capable of eliminating parasit... from hair with a single half hour treatment is mu...ches claim researchers. The dryer capable of dryi... lower temperature than that of a regular hair dry...
...The Pakistan Medical Association (PMA) plans to mo...ast bowlers Shoaib Akhtar and Mohammed Asif.// "T...tside world and the International Cricket Council ...was not meted out to the two," PMA president Umer ...
...'Sexual Harassment' at the workplace faced by wome...days and many of them are not ready to come out op...lkata, West Bengal, with 135 in-depth interviews o...d two private hospitals over a period of 11 months...
...Russia a country known for its lax regulations reg...rowning themselves in liquor without any person// ... So it comes as little surprise when recent estima...ie annually from disorders which are linked to alc...
Other Medicine News:Health News:Lice now dried to death by novel dryer 2Health News:Doctors, Nurses Face Sexual Harassment At Work Place 2
Inquire
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)
Adhesive tape sheets for sealing multiwell plates and blocks;
Microwell Plate Accessories
Medicine Products: